■Denosumab已知可增强愈伤组织的形成,同时延迟重塑。然而,其对骨折愈合的影响在文献中几乎没有报道。这个病例报告,据我们所知,是第一个报道denosumab对老年患者meta骨骨折的潜在影响的人,给药后4个月,导致骨折后17天早期负重的良好临床过程。
■一名73岁的女性因重物坠落导致右脚第二跖骨骨折。她有糖尿病史,高血压,和骨质疏松症。在维持骨折之前,她接受了7剂间隔6个月的denosumab,最后一次给药4个月前。此外,患者接受后夹板治疗6周。17天后,后续的X光片显示形成了大量的愈伤组织,没有疼痛和承受重量的能力。随后的X射线照片显示了一个大的愈伤组织,延迟了重塑。
■该病例报告表明,即使在骨质疏松症给药后4个月,denosumab仍可有效促进快速骨痂形成,尽管重建延迟。这种延迟似乎对临床结果没有负面影响,患者在骨折后17天内达到负重。
■Denosumab可能会积极影响患有meta骨骨折的老年人的骨折愈合,可能导致重塑延迟。然而,需要进一步的研究来证实这些观察结果.
UNASSIGNED: Denosumab is known to enhance callus formation while delaying remodeling. However, its effects on fracture healing are scarcely reported in the literature. This
case report, to the best of our knowledge, is the first to report the potential effect of
denosumab on a metatarsal fracture in an older adult patient, 4 months after administration, resulting in a favorable clinical course with early weight-bearing 17 days after the fracture.
UNASSIGNED: A 73-year-old female sustained a right-foot second metatarsal fracture due to the fall of a heavy object. She has a history of diabetes mellitus, hypertension, and osteoporosis. Prior to sustaining the fracture, she received seven doses of
denosumab spaced 6 months apart, with the last dose administered 4 months earlier. Furthermore, the patient was treated with a backsplint for 6 weeks. After 17 days, follow-up radiographs showed a large callus formation, with no pain and the ability to bear weight. Subsequent radiographs revealed a large callus with delayed remodeling.
UNASSIGNED: This
case report suggests that
denosumab remains effective for promoting rapid callus formation even 4 months after administration for osteoporosis, despite delayed remodeling. This delay did not seem to have negative effects on the clinical outcomes, as the patient achieved weight-bearing within 17 days after sustaining the fracture.
UNASSIGNED: Denosumab may positively influence fracture healing in older adults with metatarsal fractures, potentially leading to delayed remodeling. However, further studies are needed to confirm these observations.